Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not relate to the study; updated the page revision to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedThe page no longer displays the government funding status notice that warned information may be out of date and directed users to operating-status pages. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedMinor updates on the Study Details page, including the latest update timestamp and a new publication reference. No changes to study design, eligibility criteria, endpoints, or patient-facing information.SummaryDifference0.3%

- Check71 days agoChange DetectedSummary: The page now displays a funding-status notice and an updated version tag (v3.2.0) while removing the old version tag (v3.1.0).SummaryDifference3%

- Check78 days agoChange DetectedPage updated to version v3.1.0 and adds information about B-cell lymphoma; previous version tag v3.0.2 is removed.SummaryDifference0.1%

- Check93 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, indicating a new release. Additionally, the 'Back to Top' element was removed as a minor UI cleanup.SummaryDifference0.2%

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.